Leen Kawas on Investing in Science That Changes Lives
Biotechnology is an industry built on possibility. Each discovery carries the potential to alter the course of disease, extend lives, or transform care. Yet the path from discovery to impact is rarely straightforward. For Leen Kawas, scientist, entrepreneur, and venture investor, the central question has always been: how do we ensure that science reaches the people it is meant to help? Her answer lies in strategic investment—supporting innovation that is not only promising in the lab but also viable in the world.
Kawas is the CEO of EIT Pharma, sits on the board of Inherent Biosciences, and serves as co-founder and managing general partner of Propel Bio Partners, a venture fund dedicated to life sciences. She is also recognized for co-founding and leading Athira Pharma, where she guided late-stage clinical programs and oversaw a landmark IPO in 2020. Raising more than $400 million, she became one of only 22 women founders in the United States to take a company public. Across these roles, her focus has remained consistent: investing in science that changes lives.
From Discovery to Delivery
Kawas often emphasizes that the value of biotechnology cannot be measured solely by patents or publications. Breakthroughs must ultimately reach patients. In her view, too many promising ideas stall because they lack the capital, guidance, or infrastructure needed to translate research into therapies.
Through Propel Bio Partners, she has sought to address this gap. The fund supports entrepreneurs not only with financial backing but also with strategic expertise. Kawas explains that this dual approach helps companies navigate the complex journey from early discovery through clinical development and regulatory approval. For her, investing in science means investing in the structures that allow discoveries to mature into real-world solutions.
Choosing the Right Science
Leen Kawas is clear that not every innovation warrants the same level of support. She stresses the importance of selecting projects with both scientific merit and patient relevance. An idea may be elegant in theory, but if it fails to address an unmet need or cannot be scaled, its impact will be limited.
Her approach blends scientific rigor with entrepreneurial discipline. She evaluates potential investments by asking not only whether the science is sound but also whether it can generate measurable improvement in human health. This philosophy reflects her own training as a scientist and her experience leading a publicly traded biotech company.
Empowering Founders
One of Kawas’s core priorities is empowering the next generation of biotech founders. She knows firsthand the challenges of building a company in a sector that requires immense capital, long timelines, and resilience in the face of setbacks.
Through her work at Propel Bio Partners, she offers more than funding. She provides mentorship, networks, and strategic insight that help founders navigate the uncertainty of drug development. She argues that supporting entrepreneurs is itself a form of investing in science, since the individuals behind an idea often determine whether it succeeds.
The Importance of Patient Focus
Kawas frequently reminds colleagues and partners that patients must remain at the center of decision-making. In biotechnology, it is easy to become absorbed in technical milestones or financial benchmarks. Yet for her, the true measure of progress is the potential to change lives.
She highlights examples of therapies that, while challenging to develop, carried immense importance because they addressed conditions with few existing treatments. These are the types of projects she gravitates toward—efforts that align scientific ambition with patient urgency.
Balancing Risk and Reward
Investing in biotechnology carries inherent risk. Clinical trials fail, regulatory pathways shift, and markets evolve. Kawas acknowledges these uncertainties but insists that calculated risk is essential if science is to advance.
Her philosophy is to balance risk with foresight. By identifying promising technologies early and supporting them with robust strategy, she reduces the likelihood of failure while maximizing potential impact. This pragmatic approach has guided her through both entrepreneurial ventures and investment decisions.
A Vision for the Future
Kawas’s vision of investing in science that changes lives extends beyond individual companies. She sees biotechnology as a driver of economic growth, healthcare improvement, and social progress. Supporting innovation, in her view, is not only about delivering therapies but also about creating jobs, building industries, and expanding access to care.
She argues that the next wave of biotech breakthroughs will likely come from entrepreneurs willing to challenge convention and from investors willing to support them. By aligning resources with purpose, she believes the industry can accelerate the pace at which science moves from bench to bedside.
A Lasting Commitment
Leen Kawas’s career demonstrates that investing in science is both a personal and professional mission. Whether leading a company through the pressures of an IPO or mentoring founders at the earliest stages, she has consistently pursued opportunities that align discovery with impact.
For her, the work is not about short-term wins but about building systems that allow science to deliver on its promise. By investing in innovation that truly matters, she has helped shape a future where biotechnology is not an abstract field but a force that changes lives.
Learn more about Leen Kawas at the link below:
